Safety and Effectiveness Study of Prodisc to Spinal Fusion Surgery
NCT ID: NCT00295009
Last Updated: 2014-08-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
852 participants
INTERVENTIONAL
2001-09-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD
NCT00291018
Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain
NCT01263054
SynerFuse Spinal Fusion and Neuromodulation Proof of Concept Study
NCT04054401
Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion
NCT00810212
Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease
NCT00878579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-Level Fusion
Spinal fusion at a single lumbar level.
Spinal Fusion
A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
1-Level ProDisc
Total disc replacement with the ProDisc device at one spinal lumbar level.
ProDisc
Total disc replacement with ProDisc
2-Level Fusion
Spinal fusion at two adjacent lumbar levels.
Spinal Fusion
A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
2-Level ProDisc
Total disc replacement with the ProDisc device at two adjacent lumbar levels.
ProDisc
Total disc replacement with ProDisc
1-level ProDisc (non-randomized)
Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
ProDisc
Total disc replacement with ProDisc
2-Level ProDisc (Continued Access)
Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
ProDisc
Total disc replacement with ProDisc
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ProDisc
Total disc replacement with ProDisc
Spinal Fusion
A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 60 years.
* Failed at least 6 months of conservative treatment.
* Oswestry Low Back Pain Disability Questionnaire score of at least 20/50 (40%)(Interpreted as moderate/severe disability).
* Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
* Signed informed consent.
Exclusion Criteria
* Patients with involved vertebral endplates dimensionally smaller than 34.5mm in the medial-lateral and/or 27mm in the anterior-posterior directions.
* Known allergy to titanium, polyethylene, cobalt, chromium, or molybdenum.
* Prior fusion surgery at any vertebral level.
* Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma.
* Radiographic confirmation of facet joint disease or degeneration.
* Lytic spondylolisthesis or spinal stenosis.
* Degenerative spondylolisthesis of grade \>1.
* Back or leg pain of unknown etiology.
* Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients to determine if a DEXA scan is required. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than
* 1.0. The World Health Organization defines osteoporosis as a DEXA T score less than or equal to -2.5.
* Paget's disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed above).
* Morbid obesity defined as a body mass index \>40 or a weight more than 100 lbs. over ideal body weight.
* Pregnant or interested in becoming pregnant in the next 3 years.
* Active infection - systemic or local.
* Taking medication or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids).
* Rheumatoid arthritis or other autoimmune disease.
* Systemic disease including AIDS, HIV, Hepatitis.
* Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synthes USA HQ, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Zigler JE, Glenn J, Delamarter RB. Five-year adjacent-level degenerative changes in patients with single-level disease treated using lumbar total disc replacement with ProDisc-L versus circumferential fusion. J Neurosurg Spine. 2012 Dec;17(6):504-11. doi: 10.3171/2012.9.SPINE11717. Epub 2012 Oct 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDL-07272001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.